Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include <i>Acinetobacter</i>, Enterobacterioceae, <i>Pseudom...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/1/34 |
| _version_ | 1797542261813149696 |
|---|---|
| author | Nejat Düzgüneş Melike Sessevmez Metin Yildirim |
| author_facet | Nejat Düzgüneş Melike Sessevmez Metin Yildirim |
| author_sort | Nejat Düzgüneş |
| collection | DOAJ |
| description | Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include <i>Acinetobacter</i>, Enterobacterioceae, <i>Pseudomonas</i>, <i>Staphylococcus</i> and <i>Mycobacterium</i>. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are <i>Pseudomonas aeruginosa</i>, <i>Mycobacterium tuberculosis</i> and <i>Acinetobacter baumannii</i>. |
| first_indexed | 2024-03-10T13:28:10Z |
| format | Article |
| id | doaj.art-8e6706641ba64b08834a2fdc9a50ed21 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T13:28:10Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-8e6706641ba64b08834a2fdc9a50ed212023-11-21T08:38:12ZengMDPI AGPharmaceuticals1424-82472021-01-011413410.3390/ph14010034Bacteriophage Therapy of Bacterial Infections: The Rediscovered FrontierNejat Düzgüneş0Melike Sessevmez1Metin Yildirim2Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA 94103, USADepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, TurkeyDepartment of Pharmacy Services, Vocational School of Health Services, Tarsus University, Mersin 33400, TurkeyAntibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include <i>Acinetobacter</i>, Enterobacterioceae, <i>Pseudomonas</i>, <i>Staphylococcus</i> and <i>Mycobacterium</i>. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are <i>Pseudomonas aeruginosa</i>, <i>Mycobacterium tuberculosis</i> and <i>Acinetobacter baumannii</i>.https://www.mdpi.com/1424-8247/14/1/34lytic infectionantibiotic-resistance<i>Mycobacterium tuberculosis</i><i>Acinetobacter baumannii</i><i>Pseudomonas aeruginosa</i>phage production |
| spellingShingle | Nejat Düzgüneş Melike Sessevmez Metin Yildirim Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier Pharmaceuticals lytic infection antibiotic-resistance <i>Mycobacterium tuberculosis</i> <i>Acinetobacter baumannii</i> <i>Pseudomonas aeruginosa</i> phage production |
| title | Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier |
| title_full | Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier |
| title_fullStr | Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier |
| title_full_unstemmed | Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier |
| title_short | Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier |
| title_sort | bacteriophage therapy of bacterial infections the rediscovered frontier |
| topic | lytic infection antibiotic-resistance <i>Mycobacterium tuberculosis</i> <i>Acinetobacter baumannii</i> <i>Pseudomonas aeruginosa</i> phage production |
| url | https://www.mdpi.com/1424-8247/14/1/34 |
| work_keys_str_mv | AT nejatduzgunes bacteriophagetherapyofbacterialinfectionstherediscoveredfrontier AT melikesessevmez bacteriophagetherapyofbacterialinfectionstherediscoveredfrontier AT metinyildirim bacteriophagetherapyofbacterialinfectionstherediscoveredfrontier |